Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01408732 · ClinicalTrials.gov registry record · Phase 1

Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

A Phase 1 study of Hereditary Hemorrhagic Telangiectasia and Epistaxis, sponsored by University of Minnesota.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target
1
Study location

NCT01408732 is a Phase 1 study of Hereditary Hemorrhagic Telangiectasia and Epistaxis that has completed, run by University of Minnesota. The registered enrollment target is 18 participants, below the 1,788-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01408732, a Phase 1 study of Hereditary Hemorrhagic Telangiectasia and Epistaxis, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease.

Conditions Studied

Hereditary Hemorrhagic Telangiectasia Epistaxis

Interventions

  • OTHER Standard Treatment
  • DRUG Sclerotherapy

Study Locations (1)

Minnesota

  • University of Minnesota Otolaryngology Clinic - Minneapolis

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2011-02
Est. Completion 2014-09
Phase Phase 1

Sponsor

University of Minnesota

966 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01408732

The ClinicalTrials.gov registry entry for NCT01408732 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,788-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (99% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hereditary Hemorrhagic Telangiectasia appearing as the primary indexed condition, and to 2 interventions - of which Standard Treatment is the first listed.

NCT01408732 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT01408732 about?

NCT01408732 is a clinical study titled "Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia". The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease.

What is the current status of trial NCT01408732?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-02. Estimated completion is 2014-09.

What conditions does trial NCT01408732 study?

This clinical trial studies the following conditions: Hereditary Hemorrhagic Telangiectasia, Epistaxis.

What interventions are being tested in trial NCT01408732?

The interventions under investigation include: Standard Treatment (OTHER), Sclerotherapy (DRUG).

Who is sponsoring clinical trial NCT01408732?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01408732 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hereditary Hemorrhagic Telangiectasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hereditary Hemorrhagic Telangiectasia

All registered trials for this condition

Epistaxis

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.